Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Syros Pharmaceuticals ( (SYRS) ) has issued an update.
On February 28, 2025, Syros Pharmaceuticals announced its decision to voluntarily delist its common stock from the Nasdaq Stock Market and to deregister its common stock under the Securities Exchange Act of 1934. This decision follows the company’s failure to meet Nasdaq’s listing standards and the unsuccessful outcome of its SELECT-MDS-1 Phase 3 trial. The company plans to wind down its operations, limit expenditures, and maximize its cash position for stakeholders’ benefit. Additionally, several board members resigned, and Gerald Quirk stepped down as CEO, with Matthew Foster appointed as Chief Restructuring Officer.
More about Syros Pharmaceuticals
Syros Pharmaceuticals is a company focused on developing new standards of care for the treatment of hematologic malignancies. It has developed tamibarotene, an oral selective RARα agonist, for patients with higher-risk myelodysplastic syndrome with RARA gene overexpression.
YTD Price Performance: -37.39%
Average Trading Volume: 2,023,926
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.87M
For an in-depth examination of SYRS stock, go to TipRanks’ Stock Analysis page.